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Enteric fever is a potentially fatal multisystem illness caused by Salmonella typhi or Salmonella paratyphi [1]. It occurs worldwide where water supply and sanitation are 
substandard [2]. Enteric fever is highly endemic in developing 
countries, especially in Asia and Africa, with documented 
high prevalence among children. It is estimated that more than 
26.9 million enteric fever cases occur annually, of which 1% 
results in death [3,4].
The emergence of multidrug-resistant S. typhi has complicated 
therapy by limiting treatment options [5]. Fluoroquinolones have 
proven to be effective; however, their routine use in children 
is still restricted, and quinolone-resistant strains of S. typhi 
have begun to be reported [6,7]. Although ceftriaxone and 
other third-generation cephalosporins are still highly effective 
against S. typhi, they are considered to be less than ideal routine 
treatments [8-10]. In addition to the high cost and requirement 
of parenteral administration associated with ceftriaxone, S. typhi 
isolates resistant to this drug have begun to appear [11]. Therefore, 
other regimens are required for the treatment of enteric fever.
Azithromycin, a member of the macrolide class of antibiotics, 
possesses many characteristics for effective and convenient 
treatment of enteric fever including in vitro activity against 
many enteric pathogens, excellent penetration into most of the 
tissues, and achievement of concentrations in macrophages 
and neutrophils that are 100-fold higher than concentrations 
in serum [12-14]. In a study, 5 days after completion of 3-day 
course of azithromycin, neutrophil concentrations of the drug still 
exceeded the typical MIC for S. typhi by >20 times, whereas the 
drug was unmeasurable in the serum [13].
A recent Cochrane review reasonably concludes that clinical 
trials of enteric fever treatment over the last 40 years have not 
been ideal, and in particular, there has been a paucity of trials in 
children. From other studies, oral azithromycin administered once 
daily appears to be effective for the treatment of uncomplicated 
enteric fever in children. If these results are confirmed, this agent 
could be a convenient alternative for the treatment of enteric 
fever, especially in individuals in developing countries where 
medical resources are scarce. Hence, this study was conducted 
with the objective of studying the clinically effective drug (oral 
azithromycin versus intravenous (IV) ceftriaxone) for treating 
uncomplicated enteric fever.
MATERIALS AND METHODS
This prospective comparative study was conducted in 
Basaveshwara Medical College Hospital, Chitradurga, on 
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November 2014 to April 2016 after obtaining approval from 
Institutional Ethics Committee. A minimum sample size of 
100 cases was required using an incidence of enteric fever as 
78/2001 of total admissions in 6 months at our institution at a 
significance level of 0.05. Written informed consent of the 
parents/legal guardian was obtained before recruitment.
Children between 2 and 17 years of age admitted, with 
characteristic clinical features of uncomplicated enteric fever 
such as fever (temperature ≥38.5°C of at least 4 days), toxic 
appearance, abdominal tenderness, hepato or splenomegaly, 
coated tongue, diarrhea or constipation, and with positive blood 
culture for S. typhi were included in the study. These children 
were randomly divided into two groups to receive either 
azithromycin or ceftriaxone. Exclusion criteria were allergy to 
ceftriaxone or macrolides, major complications of enteric fever, 
inability to swallow oral medications, and treatment within past 
4 days with an antibiotic that may be effective against S. typhi. 
Complicated enteric fever was diagnosed in the presence of 
enteric fever associated with intestinal perforation, hemorrhage, 
shock, encephalopathy, and pneumonia.
A pro forma was filled for each subject which included 
the demographic details of the patient, presenting complaints, 
associated symptoms, and documented temperature. Relevant 
blood investigations such as complete blood count, widal test (for 
≥7 days fever), and blood culture were done on day 1 and 10 to 
correlate the treatment efficacy clinically and microbiologically 
using standard culture methods. Until blood culture reports 
available patients were treated symptomatically. The study groups 
received oral azithromycin 10 mg/kg/day OD for 6 days and IV 
ceftriaxone 100 mg/kg/day in 2 divided doses for 7 days [8,10].
Every day, each patient was evaluated and pro forma 
was updated with respect to temperature (axillary), appetite, 
hepatomegaly, splenomegaly, constipation/diarrhea, headache, 
and abdominal pain. Side effects of azithromycin and ceftriaxone 
were looked for and if they appear, the drug was changed to a 
safer one and the subject was excluded from the study. The patient 
was hospitalized for entire treatment period and next 3 days after 
therapy was completed. Any patient with fever or other symptoms 
suggestive of enteric fever 1 month after receiving therapy 
was evaluated and had a blood culture performed to determine 
whether there had been a relapse of enteric fever. Other samples 
were obtained for laboratory analysis as clinically indicated.
Definitions
Clinical cure was defined as the resolution of signs and symptoms 
by the end of 7 days of the treatment [1]. Defervescence/fever 
clearance was defined as the sustained period of 72 hours with 
axillary temperature of <37°C (98°F) [1]. Microbiological cure 
was defined as the sterile blood culture after treatment on day 
10 of admission [1]. Microbiological failure was defined as an 
S. typhi positive blood culture on day 10. Clinical failure was 
defined as the persistence of ≥2 enteric fever related symptoms 
or signs present at study entry or as the development of an enteric 
fever related complications. Relapse was defined as recurrence 
of fever with signs or symptoms of enteric fever within 4 weeks 
of completion of therapy along with isolation of S. typhi or 
S. paratyphi from the blood.
Statistical methods used were contingency coefficient, 
Chi-square test, independent samples “t” test using SPSS for 
windows (version 16.0). p<0.05 was taken as statistically 
significant.
RESULTS
A total of 210 children with clinical features suggestive of enteric 
fever were screened for inclusion in the study. 100 patients in sex 
ratio of 1.2:1 (male:female) with clinical enteric fever and positive 
blood culture results were included in the study. The mean age of 
cases in azithromycin group was 8.5 ± 3.4 years and in ceftriaxone 
group was 7.3 ± 2.8 years. Male:female ratio was 1.02:1 and 
1.3:1 in azithromycin and ceftriaxone group, respectively. The 
two groups were comparable with respect to demographic data, 
clinical presentations, and pretreatment laboratory evaluation.
In the current study blood culture, sampling was done before 
starting the first dose of antibiotic on day 1 of admission and 
another at 10th day of treatment, irrespective of the clinical 
outcome. Mean hemoglobin, total leukocyte count, and 
platelet counts were 12.2 g/dL, 6136/mm3, and 2.16 lakh/mm3, 
respectively, in azithromycin group while these were 11.16 g/dL, 
5609/mm3, and 3.8 lakh/mm3, respectively, in ceftriaxone group. 
The antibiotic sensitivity pattern on blood culture showed more 
susceptibility of salmonella to cefixime, ceftriaxone, azithromycin 
and chloramphenicol. No isolate was found to be resistant to 
either ceftriaxone, azithromycin or ciprofloxacin, 1 isolate was 
resistant to trimethoprim-sulfamethoxazole, 2 were resistant to 
chloramphenicol, and 3 were resistant to ampicillin.
Both antibiotic therapies were highly effective (Table 1). 
Microbiological cure was achieved in 100% patient treated with 
azithromycin and in 98% of patients treated with ceftriaxone. 
The single patient who did not respond to therapy was clinically 
healthy and, after receiving a second course of antibiotic 
therapy (chloramphenicol), achieved complete cure, including 
sterilization of the blood. Mean time taken to become afebrile 
was 5.52 days and 2.72 days for ceftriaxone and azithromycin 
Table 1: Response to treatment in both groups
Findings Azithromycin 
group N=50
Ceftriaxone 
group N=50
p value
Clinical cure 49 (98%) 43 (86%) 0.027
Microbiological cure 
by day 10
100% 98% 0.5
Mean time to become 
afebrile (in days)
2.72 5.52 0.000
Anorexia responded 
on 3rd day 
96% 76% 0.000
Relapse 0 6 
S: Significant, NS: Not significant, HS: Highly significant
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groups, respectively. 96% of the cases treated with azithromycin, 
attained defervescence by the 5th day of treatment, but only 27% 
of cases treated with ceftriaxone attained defervescence by the 
5th day of treatment. 88% defervescence was observed between 4 
and 7 days of treatment with ceftriaxone.
After hospital discharge, 6 patients from the ceftriaxone group 
returned before their scheduled 1-month follow-up visit because 
of recurrence of enteric fever related symptoms. Cultures were 
performed, and 6 patients again had S. typhi recovered from their 
blood, which indicated a relapse of infection. All 6 patients were 
treated with a second course of antibiotics, with a resolution of 
their symptoms and sterile blood cultures after completion of 
the treatment regimen. None of the 6 isolates had developed 
resistance to any antibiotic tested including ceftriaxone. No 
relapses occurred in the azithromycin group. All subjects with 
abnormal results of pretreatment laboratory analysis had normal 
values at the end of therapy.
No serious adverse events occurred. Of the minor adverse 
events, gastrointestinal symptoms were the most common in both 
the groups. Vomiting occurred more frequently among patients 
treated with azithromycin (10 patients) than among those treated 
with ceftriaxone (6 patients) (p=0.2). Vomiting was typically mild 
and transient and did not require treatment or alteration of the 
antibiotic therapy. Diarrhea was the most common adverse event 
in patients treated with ceftriaxone, occurring in 16 patients, 
compared with 11 in azithromycin group. Diarrhea also did not 
require treatment or alteration of the antibiotic therapy regimen. 
Compliance with oral azithromycin was better compared to the 
IV ceftriaxone.
DISCUSSION
Our study demonstrated that azithromycin is highly effective 
for the treatment of uncomplicated enteric fever in children. In 
this study, clinical cure was obtained in 98% of patients treated 
with azithromycin, whereas in ceftriaxone group, it was 86%. 
Microbiological cure was achieved in all patients (100%) in 
azithromycin group, whereas it was 98% in ceftriaxone group. 
These findings were comparable with studies done by Wallace 
et al. [15] and Girgis et al. [16]. In our study, 12% of the subjects 
treated with ceftriaxone had relapses within 1 month of completion 
of therapy. These data were consistent with relapse rates of 5-15% 
in other trials of ceftriaxone therapy [17]. The concentration of 
azithromycin within cells and its secretion into the biliary tree, 
in conjunction with the long half-life of the drug, likely explain 
why relapses have not occurred with it when treating a principally 
intracellular infection such as enteric fever.
A study by Tribble et al. demonstrated that a 5-day course 
of azithromycin (20 mg/kg per day, with a maximum dose of 
1000 mg/day) is effective against uncomplicated enteric fever in 
children and adolescents [18]. In our study, we used a low dose 
of azithromycin (10 mg/kg/day once a day) for 6 days and tried 
to compare with IV ceftriaxone. One of the reasons for this is 
to reduce the possible side effects related to the azithromycin 
usage [1]. The compliance was better with oral azithromycin due 
to once daily dosing as compared to the IV ceftriaxone which 
required frequent IV cannulation.
A report from Vietnam demonstrated that the duration of 
azithromycin therapy for uncomplicated enteric fever in adults 
could be decreased to 5 days [19]. The encouraging results from 
this trial prompted us to test whether a shorter treatment course 
could also be used in children and adolescents. 5 other studies 
have also demonstrated the effectiveness of azithromycin for the 
treatment of uncomplicated enteric fever in children, adolescents, 
and adults [16,18,20-22]. All these studies showed more than 90% 
clinical and microbiological cure without any serious adverse 
events or relapses.
Ceftriaxone is highly effective in the treatment of enteric 
fever but it is less than an ideal drug for its treatment. It shows 
a slow response with a mean time of 5-7 days or even longer 
to defervescence, which could be attributed to poor penetration 
capability of the drug into the cells, and thus difficult to eradicate 
the bacteria from the intracellular niche. Extended spectrum beta-
lactamase (CTX-M-15 and SHV-12 ESBLs) and CMY-2-AmpC 
beta-lactamase producing S. typhi have been reported [23]. Rise 
in resistance to third or fourth generation cephalosporins has been 
observed in many studies.
On the other hand, azithromycin possesses many characteristics 
for effective and convenient treatment of uncomplicated enteric 
fever in children with efficacy rate of more than 95% [24,25]. 
However, treatment failure rates of 9.3% have been observed in 
earlier studies [26]. Two other studies have reported a clinical cure 
rate of only 82% and 92% [20,27]. The once-daily administration 
of azithromycin, combined with the short duration of therapy, 
may improve the compliance and ease the treatment of enteric 
fever. Future research directions include whether the duration of 
therapy can be further shortened to minimize costs and further 
simplifying treatment while maintaining efficacy. We recommend 
further large scale RCT trails to draw final inference.
CONCLUSION
Oral azithromycin (10 mg/kg/day once daily for 6 days) was 
more efficacious in the treatment of uncomplicated enteric 
fever in children and adolescents as compared to IV ceftriaxone 
(100 mg/kg/day for 7 days).
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